Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors

Clinical Cancer Research

Volumn 11, Issue 10, 2005, Pages 3806-3813

  De Jonge, Maja J A ^a   Van Der Gaast, Ate ^a   Planting, André S T ^a   Van Doorn, Leny ^a   Boot, Aletta Lems Inge ^a   Wanders, Jantien ^b   Satomi, Masahiko ^c   Verweij, Jaap ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Daiichi Pharmaceuticals UK Ltd   (United Kingdom)

^c DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AURISTATIN PE; DOLASTATIN 10; LOPERAMIDE; METOCLOPRAMIDE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD SAMPLING; BODY SURFACE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESQUAMATION; DIARRHEA; DOSE CALCULATION; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG TOLERABILITY; FATIGUE; FEMALE; HEMATOLOGIC DISEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIPOSARCOMA; MALE; MASS SPECTROMETRY; MAXIMUM TOLERATED DOSE; METASTASIS; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; PAIN; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PHLEBITIS; POLYNEUROPATHY; PRIORITY JOURNAL; SKIN DISCOLORATION; SOLID TUMOR; THROMBOCYTOPENIA; ULCER; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; OLIGOPEPTIDES;

EID: 18844444472     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1937     Document Type: Article

References (27)

1. Pettit GR, Kamano Y, Herald CL, et al. The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10. J Am Chem Soc 1989;109:6883-5.
2. Pettit GR, Singh SB, Hogan F, et al. The absolute configuration and synthesis of natural (-) dolastatin 10. J Am ChemSoc 1987;111:5463-5.
3. Pettit GR, Kamano Y, Herald CL, et al. Isolation of dolastatin10-15 from the marine mollusk Dolabella auricularia. Tetrahedron 1993;49:9151-70.
4. Miyazaki K, Kobayashi M, Natsume T, et al. Synthesis and antitumour activity of novel dolastatin analogs. Chem Pharm Bull 1995;43:1706-18.
5. Natsume T, Watanabe J, Tamaoki S, Fujio N, Miyasaka K, Kobayashi M. Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin. Jpn J Cancer Res 2000;91:737-47.
6. Chaplin DJ, Pettit GR, Parkins CS, Hill SA. Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Br J Cancer 1996;74:S86-8.
7. Otani M, Natsume T. Watanabe JI, et al. TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death. Jpn J Cancer Res 2000;91:837-44.
8. Natsume T, Watanabe J, Koh Y, et al. Antitumor activity of TZT-1027 (soblidotin) against vascular endothelial growth factor-secreting human lung cancer in vivo. Cancer Sci 2003;94:826-33.
9. Watanabe J, Natsume T, Fujio N, Miyasaka K, Kobayashi M. Induction of apoptosis in human cancer cells by TZT-1027, an antimicrotubule agent. Apoptosis 2000;5:345-53.
10. Kobayashi M, Natsume T, Tamaoki S, et al. Antitumor activity of TZT-1027, a novel dolastatin 10 derivative. Jpn J Cancer Res 1997;88:316-27.
11. Fujita F, Koike M, Fujita M, Sakamoto Y, Tsukagoshi S. Antitumor effects of TZT-1027, a novel dolastatin 10 derivative, on human tumor xenografts in nude mice. Jpn J Cancer Chemother 2000;27:451-8.
12. Ogawa T, Mimura Y, Isowa K, et al. An antimicrotubule agent, TZT-1027, does not induce neuropathologic alterations which are detected after administration of vincristine or paclitaxel in animal models. Toxicol Lett 2001;121:97-106.
13. Niitani H, Hasegawa K, et al. Phase I studies of TZT-1027, a novel inhibitor of tubulin polymerization [abstract 360]. Proc NCI-EORTC Symposium on new drug in cancer therapy 1998;10.
14. Yamamoto N, Andoh M, et al: Phase I study of TZT-1027, an inhibitor of tubulin polymerization, given weekly x 3 as a 1-hour intravenous infusion in patients with solid tumors [abstract 420]. Proc Amer Soc Clin Oncol 2002;21:106a.
15. Horti J, Juhasz E, Bodrogi I, et al. A phase I trial of TZT-1027, an inhibitor of tubulin polymerization, in patients with advanced non-small cell lung cancer (NSCLC) [abstract A255]. Proc AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2003.
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment of solid tumours, J National Cancer Institute 2000;92:205-16.
17. Oguma T, Atsumi R, et al. TZT-1027: Validation of a high performance liquid chromatographic mass spectrometric method for the determination of TZT-1027 in human plasma. Daiichi Pharmaceutical Co., Ltd.; 2001 Dec 26. Study Report No: 20010582.
18. Oguma T, Atsumi R, et al. TZT-1027: Validation of a high performance liquid chromatographic mass spectrometric method for the determination of TZT-1027 in human urine. Daiichi Pharmaceutical Co., Ltd.; 2001 Dec 26. Study Report No: 20010583.
19. Schöffski P, Thate B, Beutel G, et al. Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer. Annals of Oncology 2004;15:671-9.
20. Vaishampayan U, Glode M, Du W, et al. Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma. Clin Cancer Res 2000;6:4205-8.
21. Krug LM, Miller VA, Kalemkerian GP, et al. Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer. Annals Oncol 2000;11:227-8.
22. Margolin K, Longmate J, Synold TW, et al. Dolastatin-10 in metastatic melanoma: a phase II and pharmacokinetic trial of the California Cancer Consortium. Invest new drugs 2001;19:335-40.
23. Saad ED, Kraut EH, Hoff PM, et al. Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer. Am J Clin Oncol 2002;25:451-3.
24. Rustin GJS, Galbraith SM, Anderson H, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003;21:2815-22.
25. Ralph LD, Thomson AH, Dobbs NA, Twelves C. A population model of epirubicin pharmacokinetics and application to dosage guidelines. Cancer Chemother Pharmacol 2003;52:34-40.
26. De Jongh FE, Verweij J, Loos WJ, et al. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 2001;19:3733-9.
27. Rosing H, Lustig V, Van Warmerdam LJ, et al. Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion. Cancer Chemother Pharmacol 2000;45:213-8.